Skip to content

Clinical Efficacy and Gynecological Acceptance of the Product

Evaluation of Clinical Efficacy and Gynecological Acceptability of Product for Health

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
REBEC
Registry ID
RBR-8dzth2
Enrollment
Unknown
Registered
2018-07-19
Start date
2017-07-10
Completion date
Unknown
Last updated
2025-10-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Intervention in women from 40 to 80 years of age who present postmenopausal atrophic vaginitis

Interventions

66 participants, female, aged 40 to 80 years, healthy with complaints of urinary incontinence and or vaginal atrophy. Group 1 participants with urinary incontinence and Group 2 participants with vagi
Drug
Other
C13.351.500.894.906.316

Sponsors

Medcin Instituto da Pele Ltda
Lead Sponsor
Medcin Instituto da Pele Ltda
Collaborator

Eligibility

Sex/Gender
Female
Age
40 Years to 80 Years

Inclusion criteria

Inclusion criteria: 66 female participants; aged 40 to 80 years; healthy with complaints of urinary incontinence and vaginal atrophy who wish to participate in the study.

Exclusion criteria

Exclusion criteria: Gestation or risk of gestation; use of anti-inflammatory drugs; immunosuppressants in the last 30 days or during the study; active cutaneous conditions; history of product irritation at the site of evaluation; endocrine pathologies.

Design outcomes

Primary

MeasureTime frame
To evaluate the effectiveness of the research product in the improvement of the hydration of the intimate area and the discomfort caused by urinary incontinence and genital atrophy.

Secondary

MeasureTime frame
To evaluate the perception of the volunteer regarding the sexual sensitivity, lubrication, sensation of comfort and improvement in the urinary incontinence with the use of the investigational product;;To evaluate the perception of the volunteer regarding the sexual sensitivity, lubrication, sensation of comfort as to the vaginal atrophy with the use of the investigational product;;Assess usage safety by verifying occurrences of product-related adverse events.

Countries

Brazil

Contacts

Public ContactFlávia Addor

Medcin Instituto da Pele Ltda

flavia@flaviaaddor.com.br551136542474

Outcome results

None listed

Source: REBEC (via WHO ICTRP)